Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ ACVRL1 Polyclonal Antibody

Goat Polyclonal Antibody
Supplier: Invitrogen™ PA5142099
This item is not returnable.
View return policy
Description
This antibody is tested in Peptide ELISA: antibody detection limit dilution 1:32,000.
Activin A receptor type II-like 1 (ACVRL1) is a type I cell-surface receptor for the TGF-beta superfamily of ligands. ACVRL1, similar to other type 1 receptors, has a conserved serine-threonine kinase subdomain, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. Mutations in ACVRL1 are associated with hemorrhagic telangiectasia type 2. Mutations in ACVRL1 have been linked to Fibrodysplasia Ossificans Progressiva (FOP), a rare genetic disorder characterized by the formation of bone in muscles, tendons, and other connective tissues, as well as Epicanthus.
Specifications
| ACVRL1 | |
| Polyclonal | |
| Unconjugated | |
| ACVRL1 | |
| activin A receptor like type 1; activin A receptor type II-like 1; activin A receptor type IL; activin A receptor, type II-like 1; activin A receptor, type II-like kinase 1; Activin receptor like kinase 1; activin receptor-like kinase 1; activin receptor-like kinase-1; Acvrl1; Acvrlk1; AI115505; AI427544; ALK1; ALK-1; HHT; HHT2; ORW2; R3; R-3; Serine/threonine-protein kinase receptor R3; SETHKIR; SKR3; TGF-B superfamily receptor type I; TSR-I | |
| Goat | |
| Ammonium sulfate precipitation | |
| RUO | |
| 94 | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Liquid |
| Western Blot | |
| 0.5 mg/mL | |
| TBS with 0.5% BSA and 0.02% sodium azide; pH 7.3 | |
| P37023 | |
| ACVRL1 | |
| Peptide with sequence C-KISNSPEKPKVIQ. | |
| 100 μg | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction